Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cerenis Therapeutics Holding SA - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Cerenis Therapeutics Holding SA - Product Pipeline Review - 2015', provides an overview of the Cerenis Therapeutics Holding SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cerenis Therapeutics Holding SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cerenis Therapeutics Holding SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cerenis Therapeutics Holding SA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cerenis Therapeutics Holding SA's pipeline products Reason to Buy - Evaluate Cerenis Therapeutics Holding SA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cerenis Therapeutics Holding SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cerenis Therapeutics Holding SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cerenis Therapeutics Holding SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerenis Therapeutics Holding SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Cerenis Therapeutics Holding SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Cerenis Therapeutics Holding SA Snapshot 5 Cerenis Therapeutics Holding SA Overview 5 Key Information 5 Key Facts 5 Cerenis Therapeutics Holding SA - Research and Development Overview 6 Key Therapeutic Areas 6 Cerenis Therapeutics Holding SA - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Cerenis Therapeutics Holding SA - Pipeline Products Glance 13 Cerenis Therapeutics Holding SA - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 Phase I Products/Combination Treatment Modalities 14 Cerenis Therapeutics Holding SA - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Cerenis Therapeutics Holding SA - Drug Profiles 16 (niacin + aspirin) 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 CER-001 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CER-522 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 NC-2400 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 (statin + niacin + aspirin) 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CER-209 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cerenis Therapeutics Holding SA - Pipeline Analysis 23 Cerenis Therapeutics Holding SA - Pipeline Products by Target 23 Cerenis Therapeutics Holding SA - Pipeline Products by Route of Administration 24 Cerenis Therapeutics Holding SA - Pipeline Products by Molecule Type 25 Cerenis Therapeutics Holding SA - Pipeline Products by Mechanism of Action 26 Cerenis Therapeutics Holding SA - Recent Pipeline Updates 27 Cerenis Therapeutics Holding SA - Dormant Projects 28 Cerenis Therapeutics Holding SA - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Cerenis Therapeutics Holding SA, Key Information 5 Cerenis Therapeutics Holding SA, Key Facts 5 Cerenis Therapeutics Holding SA - Pipeline by Indication, 2015 7 Cerenis Therapeutics Holding SA - Pipeline by Stage of Development, 2015 8 Cerenis Therapeutics Holding SA - Monotherapy Products in Pipeline, 2015 9 Cerenis Therapeutics Holding SA - Combination Treatment Modalities in Pipeline, 2015 10 Cerenis Therapeutics Holding SA - Partnered Products in Pipeline, 2015 11 Cerenis Therapeutics Holding SA - Partnered Products/ Combination Treatment Modalities, 2015 12 Cerenis Therapeutics Holding SA - Phase II, 2015 13 Cerenis Therapeutics Holding SA - Phase I, 2015 14 Cerenis Therapeutics Holding SA - Preclinical, 2015 15 Cerenis Therapeutics Holding SA - Pipeline by Target, 2015 23 Cerenis Therapeutics Holding SA - Pipeline by Route of Administration, 2015 24 Cerenis Therapeutics Holding SA - Pipeline by Molecule Type, 2015 25 Cerenis Therapeutics Holding SA - Pipeline Products by Mechanism of Action, 2015 26 Cerenis Therapeutics Holding SA - Recent Pipeline Updates, 2015 27 Cerenis Therapeutics Holding SA - Dormant Developmental Projects,2015 28 Cerenis Therapeutics Holding SA, Other Locations 29
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.